Curemark Moderates Autism Panel at Life Sciences Summit 2010
RYE, N.Y., Oct. 11 /PRNewswire/ -- Dr. Joan Fallon, founder and CEO of Curemark, LLC , (www.curemark.com ), a drug research and development company focused on the treatment of neurological diseases, moderated the neuroscience roundtable focused on autism at the Life Sciences Summit 2010, held September 22-23 in Hauppauge, New York.
Sponsored by the State University of New York at Stony Brook, Brookhaven National Laboratories and Cold Spring Harbor Laboratories, the Life Sciences Summit focused on forging partnerships between biopharmaceutical companies and companies emerging from academia to accelerate biomedical solutions in areas including infectious disease, neuroscience, oncology and regenerative medicine. In addition to serving as panel moderator, Dr. Fallon presented an update on Curemark's autism treatment CM-AT , currently in Phase III clinical trials, at the conference's Emerging Company and Innovator's Showcase.
"The Life Sciences Summit brought together researchers, scientists and representatives of companies working at the forefront of new medical developments, who shared and exchanged ideas in this very conducive forum. The discussion at the Roundtable highlighted some of the latest research in identifying possible causes of autism as well promising new therapies," she said.
Participating at the Roundtable entitled "Autism Spectrum Disorder: Recent Advances in the Development of Symptomatic Treatments" were Joseph Buxbaum, PhD, MSc, principal investigator, Laboratory of Molecular Neuropsychiatry, Mount Sinai School of Medicine; Deborah A. Pearson, PhD, professor, Division of Child and Adolescent Psychiatry, Department of Psychiatry and Behavioral Sciences, University of Texas Medical School at Houston; John Spiro, PhD, senior associate director for research, Simons Foundation; and Larry J.